Document Detail

Aggressive natural killer cell leukemia/lymphoma: case report, use of telesynergy and review of the literature.
MedLine Citation:
PMID:  15360011     Owner:  NLM     Status:  MEDLINE    
Natural killer cell malignancies, although increasingly recognized, remain rare tumors within the USA and Europe. They are somewhat more common in Asia, and have been best characterized within this population. We present a case of a young Caucasian woman who presented acutely with an aggressive natural killer cell leukemia/lymphoma. Use of Telesynergy technology enabled a transatlantic telemedicine conference with colleagues in a center of expertise. Unfortunately the patient was ultimately refractory to both conventional chemotherapy and Campath-1H and her disease course was fulminant, as has been described previously in this condition. We review the possible therapeutic options for this extremely aggressive malignancy and briefly discuss our center's experience of telemedicine technology.
Joanne Murdock; Elaine S Jaffe; Wyndham H Wilson; Damian T McManus; H Denis Alexander; T C M Curly Morris
Publication Detail:
Type:  Case Reports; Journal Article; Review    
Journal Detail:
Title:  Leukemia & lymphoma     Volume:  45     ISSN:  1042-8194     ISO Abbreviation:  Leuk. Lymphoma     Publication Date:  2004 Jun 
Date Detail:
Created Date:  2004-09-13     Completed Date:  2004-10-08     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  9007422     Medline TA:  Leuk Lymphoma     Country:  England    
Other Details:
Languages:  eng     Pagination:  1269-73     Citation Subset:  IM    
Haematology Department, Belfast City Hospital, Belfast, BT9 7AB, N. Ireland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm / therapeutic use*
Drug Resistance, Neoplasm
Fatal Outcome
Killer Cells, Natural / immunology*,  pathology*
Leukemia / drug therapy,  immunology,  pathology*
Lymphoma / drug therapy,  immunology,  pathology*
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antibodies, Neoplasm; 3A189DH42V/alemtuzumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Richter's syndrome in the brain first manifested as an ischaemic stroke.
Next Document:  Somatostatin receptor scintigraphy in MALT lymphoma of the lacrimal gland treated with rituximab.